<DOC>
	<DOCNO>NCT02498392</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety tolerability JNJ-42165279 participant major depressive disorder ( MDD ) anxiety symptom inadequate response treatment selective serotonin reuptake inhibitor ( SSRI ) serotonergic/noradrenergic reuptake inhibitor ( SNRI ) .</brief_summary>
	<brief_title>An Efficacy , Safety Tolerability Study JNJ-42165279 Participants With Major Depressive Disorder With Anxious Distress</brief_title>
	<detailed_description>This multicenter , double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled , randomize , parallel-group study participant Major Depressive Disorder ( MDD ) Anxious Distress . Participants treatment initiate SSRI/SNRI allow protocol evaluate investigation site . The site assessment review validated independent central rater . The review include clinical history MDD , SSRI/SNRI treatment adequate dose duration current episode depression , current symptom severity Hamilton Depression Rating Scale ( HDRS17 ) . Enrolled participant maintain SSRI/SNRI treatment throughout study determine whether additional treatment JNJ-4216579 reduce symptom MDD anxious distress.The study consist 3 phase : Screening Phase 4 week , 11-week double-blind Treatment Phase , 3-week post-treatment ( follow ) Phase . The double-blind treatment Phase trial consist 3 period . The first period placebo lead-in double-blind duration , participant enter treatment period randomly assign JNJ-42165279 continuation placebo 6 week . Participants successfully complete treatment period prior end Week 11 , treat placebo remain time double-blind phase study , vary depend duration placebo lead-in specific participant . The total study duration participant approximately 18 week . Efficacy safety JNJ-42165279 evaluate . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Participant must meet Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) 5 diagnostic criterion major depressive disorder ( MDD ) Anxious Distress Participants diagnosis comorbid Generalized Anxiety Disorder , Social Anxiety Disorder , Panic Disorder may include , investigator considers MDD Anxious Distress primary diagnosis ( confirmed independent central rater screen ) Participants must treat approve SSRI/SNRI antidepressant least 6 continuous week , validate independent central rater contract sponsor A 17item Hamilton Depression Rating Scale ( HDRS17 ) total score great equal ( &gt; = ) 18 HDRS17 anxiety/somatization factor score &gt; =7 screening , assess site rater review independent central rater Day 1 Participant must willing able adhere prohibition restriction Participant Body mass index ( BMI = weight/height2 ) must 18 35 kilogram per square meter ( kg/m^2 ) inclusive Has psychiatric condition , include , limited , MDD psychotic feature , bipolar disorder , obsessivecompulsive disorder , posttraumatic stress disorder , borderline personality disorder , eat disorder , schizophrenia Has length current Major Depressive Episode ( MDE ) great ( &gt; ) 6 month Has 1 fail antidepressant treatment adequate dose duration current MDE , Not include inadequate response current selective serotonin reuptake inhibitor ( SSRI ) serotonergic/noradrenergic reuptake inhibitor ( SNRI ) antidepressant Has initiate psychotherapy specific MDD ( cognitive behavioral , behavioral , interpersonal therapy ) current episode depression within 6 week prior Screening Has current recent history clinically significant suicidal ideation within past 6 month , history suicidal behavior within past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Anxiety symptom</keyword>
	<keyword>JNJ-42165279</keyword>
</DOC>